Social media

We’re proud to announce the expansion of oncology research within ICON’s Accellacare Site Network through the Brian Moran Cancer Institute at Duly Health and Care in Illinois. This strategic expansion strengthens our ab...

ICON is proud to be recognised among the top global companies in the world for female employees. As of 31 December 2024, women make up 70% of our workforce and hold 60% of director-level and above roles—a powerful refle...

Join us at #OCTWestCoast on 11 February at 9am, for a special featured presentation by ICON’s Travis Caudill. Discover if AI is enough and why smarter site identifications still need human-centred strategies. This sessi...

When exploring roles at a global organisation, you may come across terms like applicant tracking systems, often referred to as ATS. As part of our hiring clarity series, we’ve shared a short resource that explains what ...

Careers in finance look different when you are close to the centre of a global organisation. At ICON’s Dublin headquarters, our finance professionals gain exposure across regions, work closely with senior leaders, and a...

Is AI enough? Artificial intelligence has revolutionised site identification, but it’s not the whole story. At SCOPE 2026, join Travis Caudill, VP – Feasibility, Site Selection & Medical Informatics, as he explores why s...

Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s...

In 2025 ICON was recognised for its commitment to building an inclusive workplace. Learn more. https://ow.ly/uWXN50XSPUE

At ICON, we understand that exploring a new career opportunity comes with questions. Having a clear sense of what to expect can make the experience feel more straightforward. This week, we’re sharing a five part series ...

The development of longer-acting and more potent NUSH receptor agonists, like semaglutide, has helped clarify the link between aberrant glucose metabolism and a range of diseases. Learn how to embrace the multi-indicatio...

PubsHub Journals & Congresses now includes publication AI policy guidelines, ensuring ethical use and transparency in research. Whether you use AI to analyze data or draft manuscripts, learn what’s required for complianc...

ICON is heading to SCOPE 2026 From labs and patient solutions to site strategies and biosimilars, our experts will be on the ground in Orlando from 2–5 February. We’re ready to share insights on accelerating clinical de...